Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects

NCT04711343 | Completed Phase 1

• 1 other identifier: BAT-2306-001-CR
• Study Type: interventional
• Target: 216
• Locations: 1 country
• Sites: 1

Brief Summary

It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2306 Injection vs Cosentyx® (EU-licensed and US-licensed) in healthy Chinese male subjects. A total of 216 healthy male subjects are planned to be included and randomized at a ratio of 1:1:1 to receive single 150mg BAT2306 Injection or Cosentyx® (EU-licensed and US-licensed).

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics Endpoint：Peak plasma concentration (Cmax)

  Pharmacokinetics Endpoint：Peak plasma concentration (Cmax)

  0-5months

• Pharmacokinetics Endpoint：Area under the plasma concentration versus time curve (AUC0-inf)

  Pharmacokinetics Endpoint：Area under the plasma concentration versus time

  0-5months

Study Arms (3)

BAT2306 injection

EXPERIMENTAL

150mg /1ml; subcutaneous injection

Drug: BAT2306

Cosentyx (US-licensed)

ACTIVE COMPARATOR

150mg /1ml; subcutaneous injection

Drug: Cosentyx (US-licensed)

Cosentyx (EU-licensed)

ACTIVE COMPARATOR

150mg /1ml; subcutaneous injection

Drug: Cosentyx (EU-licensed)

Interventions

BAT2306 DRUG

150mg/1 ml; single dose；prefilled syringe; subcutaneous injection

BAT2306 injection

Cosentyx (US-licensed) DRUG

150mg/1 ml; single dose；prefilled syringe; subcutaneous injection

Also known as: Secukinumab

Cosentyx (US-licensed)

Cosentyx (EU-licensed) DRUG

150mg/1 ml; single dose；prefilled syringe; subcutaneous injection

Also known as: Secukinumab

Cosentyx (EU-licensed)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Chinese male healthy subjects aged from 18 to 55 years (including the boundary value)；
• BMI between 18-28kg/m2 (including boundary value) and body weight between 55-85kg;
• Normal physical examination results or abnormal with no clinical significance according to the doctor's judgment;
• The subject (including partner) has no pregnancy plan or sperm donation plan during the whole trial period and within 6 months after the completion of the study, and voluntarily adopts effective contraceptive measures;
• Sign the informed consent before joining the study, and fully understand the content, process and possible risks;
• Willing and able to comply with the visits and treatments of the trial protocol.

You may not qualify if:

• Clinical laboratory examination results are abnormal and with clinical significance, or other clinical findings indicate diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, tumor, pulmonary, immune, mental or cardiovascular and cerebrovascular diseases) with clinical significance within one year prior to screening；
• ECG is abnormal and has clinical significance (judged by the investigator);
• With active infection within two months before screening, including acute and chronic infection and local infection;
• Hepatitis B and/or Hepatitis C; or HIV antigen/antibody positive; or Treponema pallidum antibody positive;
• Having taken any prescription drug, over-the-counter drug, any vitamin product or herbal medicine within 28 days before screening (or within 5 half-lives of the above drugs, whichever is longer);
• Having participated in drug clinical trials within 3 months before the study administration, or planning to participate in other drug clinical trials during the study period;
• Acute disease occurred or with concomitant medication from the screening to use of the study drug; major injury or surgery or fracture occurred within 4 weeks before enrollment, or surgery was planned during the study;
• Having used Secukinumab (or its biosimilars) or interleukin (IL-17) targeting agents, or having used any biological products or monoclonal antibodies within 3 months before screening (or within 5 half-lives of the drugs, whichever is longer);
• Having received within 12 weeks prior to initiating treatment or planning to receive live vaccines during the study;
• Suspected or confirmed as allergic constitution (allergic to variety of drugs or food), or allergic to Secukinumab, or severe allergic or allergic reaction to monoclonal antibody;
• Blood donation or massive blood loss (\> 450 ml) within 3 months before using the study drug, or planning to donate blood during the study, or having received blood transfusion within 8 weeks before screening;
• Positive urine drug screening or drug abuse history or drug use in the past five years;
• Employees or relatives of all investigators, clinical centers, clinical research organizations or sponsors cannot be included in the group;
• Subjects considered unsuitable by the investigators.

Sponsors & Collaborators

• Bio-Thera Solutions: lead

Study Sites (1)

The First Hospital of Jilin University

Changchun, Jilin, China

Location

MeSH Terms

Conditions

Psoriasis

Interventions

secukinumab

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Yanhua Ding

  The First Hospital of Jinlin University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 12, 2021
• First Posted: January 15, 2021
• Study Start: June 8, 2022
• Primary Completion: May 3, 2023
• Study Completion: June 5, 2023
• Last Updated: August 28, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)